GNRH1 and hypoalphalipoproteinemia, primary, 1: iPSCs may be also used to test therapies targeting not only GnRH release, but also the serotoninergic and dopaminergic neurotransmission, in order to improve the behavioral features of FHA, taking into account the personal response mediated by the epigenetic profile of each patient.